科研速览 · Science Skim继续刷下去 · Keep skimming →
◆ International journal of antimicrobial agents2026-09-23

A clinical prediction model to support risk-adapted fibrinogen monitoring during tigecycline therapy: multicenter development and validation.

Jinlin Guo, Xinfeng Cai, Yayu Huo, Hongping Wen, Jun Li, Shuming Guo, Lin Hao, Xinjing Wu, Wenjing Hou, Shufeng Li, Haoyan Jia, Ruigang Hou

原始摘要(英文原文)· Original abstract
Uniform fibrinogen monitoring during tigecycline therapy may be inefficient, whereas conventional absolute thresholds can miss deterioration in patients with a marked relative decline from a high baseline. We developed and validated an initiation-time clinical prediction model to support risk-adapted fibrinogen monitoring during tigecycline therapy. In this multicenter prognostic study across tertiary hospitals in China, retrospective model development and external validation were followed by prospective temporal validation. Eligible adults received tigecycline for at least 72 h, had baseline fibrinogen of at least 2.0 g/L, and underwent at least one on-treatment reassessment. The primary outcome was study-defined fibrinogen deterioration, defined as a decline of at least 50% from baseline and/or a nadir below 1.5 g/L. A logistic regression model using variables available at treatment initiation was evaluated for discrimination, calibration, and decision-analytic utility. Among 1411 eligible patients, 332, 760, and 319 were included in the development, external validation, and prospective validation cohorts, respectively; strict case/control analysis sets comprised 222, 514, and 234 patients. The final 4-variable model included age, tigecycline daily dose, total bilirubin, and baseline fibrinogen, and was intended for monitoring-intensity stratification, not treatment selection. Optimism-corrected development, external validation, and prospective validation AUCs were 0.755, 0.731, and 0.714, respectively. In the full prospective eligible cohort (N=319), discrimination attenuated (AUC 0.693) and calibration drift supported local recalibration before implementation. After recalibration, decision-curve analysis favored model-guided monitoring at prespecified threshold probabilities. This simple initiation-time model may support risk-adapted monitoring, but local recalibration should precede threshold-based use in new settings.
读原文 · Read the paper ↗

AI 追问PRO

登录后使用 AI 追问

讨论区

登录后参与讨论

相关论文 · Related

A clinical prediction model to support risk-adapted fibrinogen monitoring during tigecycline therapy: multicenter development and validation. — 科研速览 Science Skim